Literature DB >> 2457659

Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity.

E O'Hearn1, G Battaglia, E B De Souza, M J Kuhar, M E Molliver.   

Abstract

The psychotropic amphetamine derivatives 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) have been used for recreational and therapeutic purposes in man. In rats, these drugs cause large reductions in brain levels of serotonin (5-HT). This study employs immunocytochemistry to characterize the neurotoxic effects of these compounds upon monoaminergic neurons in the rat brain. Two weeks after systemic administration of MDA or MDMA (20 mg/kg, s.c., twice daily for 4 d), there is profound loss of serotonergic (5-HT) axons throughout the forebrain; catecholamine axons are completely spared. Regional differences in drug toxicity are exemplified by partial sparing of 5-HT axons in hippocampus, lateral hypothalamus, basal forebrain, and in some areas of neocortex. The terminals of 5-HT axons are selectively ablated, while axons of passage and raphe cell bodies are spared. Thickened preterminal fibers exhibit increased staining due to damming-up of neurotransmitter and other axonal constituents. Fine 5-HT axon terminals are extremely vulnerable to these drugs, whereas terminal-like axons with large varicosities survive, raising the possibility that some 5-HT axons may be resistant to the neurotoxic effects. At short survivals, visualization of greatly swollen, fragmented 5-HT axons provides anatomic evidence for degeneration of 5-HT projections. The results establish that MDA and MDMA produce structural damage to 5-HT axon terminals followed by lasting denervation of the forebrain. Both drugs have similar effects, but MDA produces a greater reduction of 5-HT axons than does MDMA at the same dosage. The selective degeneration of 5-HT axons indicates that these drugs may serve as experimental tools to analyze the organization and function of 5-HT projections. Caution should be exercised until further studies determine whether these compounds may be hazardous in man.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457659      PMCID: PMC6569396     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  91 in total

1.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

2.  (±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.

Authors:  Ann M Hemmerle; Jonathan W Dickerson; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams; Kim B Seroogy
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

3.  Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy").

Authors:  J Sharkey; D E McBean; P A Kelly
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 4.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

5.  MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.

Authors:  Stuart A Collins; Gary A Gudelsky; Bryan K Yamamoto
Journal:  Eur J Pharmacol       Date:  2015-04-30       Impact factor: 4.432

6.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

7.  Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Authors:  Brigitta Balogh; Eszter Molnar; Rita Jakus; Linda Quate; Henry J Olverman; Paul A T Kelly; Sandor Kantor; Gyorgy Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons.

Authors:  Laura Orio; Noemi Llopis; Elisa Torres; Maria Izco; Esther O'Shea; M Isabel Colado
Journal:  Neurotox Res       Date:  2009-09-24       Impact factor: 3.911

9.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

10.  Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.

Authors:  Karen L Hanson; Monica Luciana; Kristin Sullwold
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.